Bret R. Sellman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bret R. Sellman has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Vancheswaran Gopalakrishnan
Bioinformatics, Infectious Disease, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878, USA
3 shared publications - Alexander I. Spira
Virginia Cancer Specialists Research Institute, Fairfax, VA
1 shared publication - Ann Marie Stanley
Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA
1 shared publication - Christine Tkaczyk
Bacteriology, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, Maryland
1 shared publication - Davey B. Daniel
Tennessee Oncology 8 , Nashville, Tennessee
1 shared publication - David R. Spigel
Sarah Cannon Research Institute, Nashville, TN
1 shared publication
Latest Publications
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
683. Understanding Clostridioides difficile toxinB gene conservation through surveillance of public data
Clostridioides difficile infection (CDI) is the leading cause of antibiotic and healthcare-associated infective diarrhea. It is linked to 365,000 infections and causes approximately 20,000 deaths annually in the US. CDI is mediated by the action of toxin B (TcdB) in humans. Monoclonal antibodies (mAbs) that neutralize TcdB function have shown protection against CDI in preclinical models and more recently in the clinic. Several regions on the TcdB gene have been targeted by therapeutic mAbs including the glucosyltransferase (GTD) and the C-terminal combined repetitive oligopeptides (CROPS) domains. We have developed AZD5148, an anti-TcdB mAb targeting a region within the GTD. To understand its strain coverage, we examined sequence variations of GTD including the AZD5148 epitope in contemporary C. difficile strains utilizing a public data repository. 8,085 assembled C. difficile genomes collected between 2015-2022 were obtained from Enterobase. These were annotated with Prokka to identify the TcdB gene coding sequence, and subsequently aligned to the R20291 strain reference. Phylogeny was determined with ParSnp and visualized using iTol. From the aligned sequences, variants were identified using an in-house tool (RADAR). A majority of the C. difficile genomes deposited were from North America, specifically the United States. Ribotype (RT) information was available for 9.6% of the genomes with RT-078 being the most common. Phylogenetic analysis did not reveal any patterns by geography or collection year, though clades tended to be associated with ribotypes. Degree of conservation was calculated at each TcdB genomic residue and was evaluated both regionally and temporally. We found GTD to be highly conserved in US isolates as well as globally. Additionally, among contact residues for AZD5148, any variations observed were single, and were seen for positions 323 (Y-H), 329 (G-E), 349 (V-A), and 350 (L-I). These findings have important implications for drug development including for AZD5148. Specifically, our findings reveal that the GTD domain of the TcdB gene has lower variance globally over the last 7 years making it a promising target for a C. difficile TcdB neutralizing mAb. Kelly Mulholland, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Victoria Godfrey, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Ann Marie Stanley, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Tyler Brady, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Bret R. Sellman, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Christine Tkaczyk, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Vancheswaran Gopalakrishnan, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access683. Understanding Clostridioides difficile toxinB gene conservation through surveillance of public data
Clostridioides difficile infection (CDI) is the leading cause of antibiotic and healthcare-associated infective diarrhea. It is linked to 365,000 infections and causes approximately 20,000 deaths annually in the US. CDI is mediated by the action of toxin B (TcdB) in humans. Monoclonal antibodies (mAbs) that neutralize TcdB function have shown protection against CDI in preclinical models and more recently in the clinic. Several regions on the TcdB gene have been targeted by therapeutic mAbs including the glucosyltransferase (GTD) and the C-terminal combined repetitive oligopeptides (CROPS) domains. We have developed AZD5148, an anti-TcdB mAb targeting a region within the GTD. To understand its strain coverage, we examined sequence variations of GTD including the AZD5148 epitope in contemporary C. difficile strains utilizing a public data repository. 8,085 assembled C. difficile genomes collected between 2015-2022 were obtained from Enterobase. These were annotated with Prokka to identify the TcdB gene coding sequence, and subsequently aligned to the R20291 strain reference. Phylogeny was determined with ParSnp and visualized using iTol. From the aligned sequences, variants were identified using an in-house tool (RADAR). A majority of the C. difficile genomes deposited were from North America, specifically the United States. Ribotype (RT) information was available for 9.6% of the genomes with RT-078 being the most common. Phylogenetic analysis did not reveal any patterns by geography or collection year, though clades tended to be associated with ribotypes. Degree of conservation was calculated at each TcdB genomic residue and was evaluated both regionally and temporally. We found GTD to be highly conserved in US isolates as well as globally. Additionally, among contact residues for AZD5148, any variations observed were single, and were seen for positions 323 (Y-H), 329 (G-E), 349 (V-A), and 350 (L-I). These findings have important implications for drug development including for AZD5148. Specifically, our findings reveal that the GTD domain of the TcdB gene has lower variance globally over the last 7 years making it a promising target for a C. difficile TcdB neutralizing mAb. Kelly Mulholland, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Victoria Godfrey, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Ann Marie Stanley, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Tyler Brady, MS, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Bret R. Sellman, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Christine Tkaczyk, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Vancheswaran Gopalakrishnan, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds
- Top Cited PapersOpen Access
- 14 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (11) , 2394-2411
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platform trial to examine novel neoadjuvant immuno-oncology combinations for patients with resectable NSCLC, using major pathologic response (MPR) rate as the primary endpoint. Eighty-three patients received a single cycle of treatment: 26 received durvalumab (anti–PD-L1) monotherapy, 21 received durvalumab plus oleclumab (anti-CD73), 20 received durvalumab plus monalizumab (anti-NKG2A), and 16 received durvalumab plus danvatirsen (anti-STAT3 antisense oligonucleotide). MPR rates were higher for patients in the combination arms versus durvalumab alone. Safety profiles for the combinations were similar to those of durvalumab alone. Multiplatform immune profiling suggested that improved MPR rates in the durvalumab plus oleclumab and durvalumab plus monalizumab arms were associated with enhanced effector immune infiltration of tumors, interferon responses and markers of tertiary lymphoid structure formation, and systemic functional immune cell activation. Significance: A neoadjuvant platform trial can rapidly generate clinical and translational data using candidate surrogate endpoints like MPR. In NeoCOAST, patients with resectable NSCLC had improved MPR rates after durvalumab plus oleclumab or monalizumab versus durvalumab alone and tumoral transcriptomic signatures indicative of augmented immune cell activation and function. See related commentary by Cooper and Yu, p. 2306. This article is featured in Selected Articles from This Issue, p. 2293
- 14 September 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (11) , 2394-2411
Top Cited PapersOpen AccessNeoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platform trial to examine novel neoadjuvant immuno-oncology combinations for patients with resectable NSCLC, using major pathologic response (MPR) rate as the primary endpoint. Eighty-three patients received a single cycle of treatment: 26 received durvalumab (anti–PD-L1) monotherapy, 21 received durvalumab plus oleclumab (anti-CD73), 20 received durvalumab plus monalizumab (anti-NKG2A), and 16 received durvalumab plus danvatirsen (anti-STAT3 antisense oligonucleotide). MPR rates were higher for patients in the combination arms versus durvalumab alone. Safety profiles for the combinations were similar to those of durvalumab alone. Multiplatform immune profiling suggested that improved MPR rates in the durvalumab plus oleclumab and durvalumab plus monalizumab arms were associated with enhanced effector immune infiltration of tumors, interferon responses and markers of tertiary lymphoid structure formation, and systemic functional immune cell activation. Significance: A neoadjuvant platform trial can rapidly generate clinical and translational data using candidate surrogate endpoints like MPR. In NeoCOAST, patients with resectable NSCLC had improved MPR rates after durvalumab plus oleclumab or monalizumab versus durvalumab alone and tumoral transcriptomic signatures indicative of augmented immune cell activation and function. See related commentary by Cooper and Yu, p. 2306. This article is featured in Selected Articles from This Issue, p. 2293
- 1 October 2020
- Published by Elsevier in European Urology
- Vol. 78 (4) , 544-545
Antibiotics and Immunotherapy: Too Much of Anything is Bad!
- 1 October 2020
- Published by Elsevier in European Urology
- Vol. 78 (4) , 544-545
Antibiotics and Immunotherapy: Too Much of Anything is Bad!